date:Dec 14, 2022
, says Lars Rebien Srensen, chairman of Novo Holdings and the Novo Nordisk Foundation. Combining the two companies will create a global leader in biosolutions.
As long-term shareholders in both Novozymes and Chr. Hansen, we are in full support of the plans to combine the two companies, adds Kasim Kutay, CEO of Novo Holdings. Due to our strong belief in the commercial, strategic, and long-term financial merits of this transaction, we are willing to accept a less favorable exchange ratio for our